Graham Vioxx study
This article was originally published in The Tan Sheet
"Patients taking Vioxx had a 34% higher chance of coronary heart disease when compared with people who used other NSAIDs," David Graham, MD, FDA Office of Drug Safety, et al., conclude in a study published online by The Lancet Jan. 25. The study indicated Merck's Vioxx may have caused 88,000-140,000 excess cases of coronary heart disease since its launch. Researchers analyzed data on 1.4 mil. people who used either rofecoxib, celecoxib, ibuprofen or naproxen from January 1999 through December 2001. Participants who took naproxen experienced a 14% increased risk of coronary heart disease compared to those using other NSAIDs. "Because of limited power, we were unable to fully address whether the cardiovascular risk associated with rofecoxib varied by duration of use," Graham et al. note...
You may also be interested in...
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
India is allowing importers and manufacturers of certain devices – for whom new licensing requirements came into effect on 1 January – to continue marketing their products for six months if they have already applied for a license. See what Rajiv Nath from the Association of Indian Medical Device Industry (AiMeD) said about it here.
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.